

FROM THE EDITOR'S DESK

From the Editor's desk. . .

R. Moreau, R. Bataller, T. Berg, S. Lotersztajn, J. Zucman-Rossi and R. Jalan 819

EDITORIALS

EASL Recognition Award Recipient 2019: Prof. Deirdre Kelly
U. Baumann 822

EASL Recognition Award Recipient 2019: Prof. Vincenzo Mazzaferro
P. Majno-Hurst 824

EASL International Recognition Award Recipient 2019: Prof. Flair José Carrilho
V. Arroyo 826

Assessment of renal function in cirrhosis: Sarcopenia, gender and ethnicity matter
C. Francoz and E. Sola 828

RESEARCH ARTICLES

Viral Hepatitis

Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation
H. Fontaine, L. Alric, J. Labreuche, B. Legendre, A. Louvet, C. Antoine, C.M. Legendre, M. Hazzan, N. Kamar, S. Dharancy, S. Pol, A. Duhamel and P. Mathurin 831

Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care
T. Papaluca, L. McDonald, A. Craigie, A. Gibson, P. Desmond, D. Wong, R. Winter, N. Scott, J. Howell, J. Doyle, A. Pedrana, A. Lloyd, M. Stooze, M. Hellard, D. Iser and A. Thompson 839

Cirrhosis

Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex
J.-J. Yoo, S.G. Kim, Y.S. Kim, B. Lee, M.H. Lee, S.W. Jeong, J.Y. Jang, S.H. Lee, H.S. Kim, Y.D. Kim and G.J. Cheon 847

Transplantation

Survival advantage for patients accepting the offer of a circulatory death liver transplant
R. Taylor, E. Allen, J.A. Richards, M.A. Goh, J. Neuberger, D. Collett, G.J. Pettigrew and Liver Advisory Group to NHS Blood and Transplant 855

Cancer

Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients

A. Doyle, A. Gorgen, H. Muaddi, A.D. Aravinthan, A. Issachar, O. Mironov, W. Zhang, J. Kachura, R. Beecroft, S.P. Cleary, A. Ghanekar, P.D. Greig, I.D. McGilvray, M. Selzner, M.S. Cattral, D.R. Grant, L.B. Lilly, N. Selzner, E.L. Renner, M. Sherman and G. Sapisochin 866

Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules

Z. Mariño, A. Darnell, S. Lens, V. Sapena, A. Díaz, E. Belmonte, C. Perelló, J.L. Calleja, M. Varela, M. Rodriguez, C. Rodriguez de Lope, S. Llerena, X. Torras, A. Gallego, M. Sala, R.M. Morillas, B. Minguez, J. Llaneras, S. Coll, J.A. Carrion, M. Iñarrairaegui, B. Sangro, R. Vilana, M. Sole, C. Ayuso, J. Rios, X. Forns, J. Bruix and M. Reig 874

Association between physical activity and risk of hepatobiliary cancers: A multinational cohort study

S.E. Baumeister, S. Schlesinger, K. Aleksandrova, C. Jochem, M. Jenab, M.J. Gunter, K. Overvad, A. Tjønneland, M.-C. Boutron-Ruault, F. Carbonnel, A. Fournier, T. Kühn, R. Kaaks, T. Pischon, H. Boeing, A. Trichopoulou, C. Bamia, C. La Vecchia, G. Masala, S. Panico, F. Fasanelli, R. Tumino, S. Grioni, B. Bueno de Mesquita, R. Vermeulen, A.M. May, K.B. Borch, S.O. Oyeyemi, E. Ardanaz, M. Rodríguez-Barranco, M. Dolores Chirlaque López, M. Felez-Nobrega, E. Sonestedt, B. Ohlsson, O. Hemmingsson, M. Werner, A. Perez-Cornago, P. Ferrari, M. Stepien, H. Freisling, K.K. Tsilidis, H. Ward, E. Riboli, E. Weiderpass and M.F. Leitzmann 885

Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study

Q. Wang, D. Xia, W. Bai, E. Wang, J. Sun, M. Huang, W. Mu, G. Yin, H. Li, H. Zhao, J. Li, C. Zhang, X. Zhu, J. Wu, J. Li, W. Gong, Z. Li, Z. Lin, X. Pan, H. Shi, G. Shao, J. Liu, S. Yang, Y. Zheng, J. Xu, J. Song, W. Wang, Z. Wang, Y. Zhang, R. Ding, H. Zhang, H. Yu, L. Zheng, W. Gu, N. You, G. Wang, S. Zhang, L. Feng, L. Liu, P. Zhang, X. Li, J. Chen, T. Xu, W. Zhou, H. Zeng, Y. Zhang, W. Huang, W. Jiang, W. Zhang, W. Shao, L. Li, J. Niu, J. Yuan, X. Li, Y. Lv, K. Li, Z. Yin, J. Xia, D. Fan, G. Han and on behalf of China HCC-TACE Study Group 893

A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma

Q.-g. Xu, S.-x. Yuan, Q.-f. Tao, J. Yu, J. Cai, Y. Yang, X.-g. Guo, K.-y. Lin, J.-z. Ma, D.-s. Dai, Z.-g. Wang, F.-m. Gu, L.-h. Zhao, L.-q. Li, J.-f. Liu, S.-h. Sun, Y.-j. Zang, H. Liu, F. Yang and W.-p. Zhou 904

Molecular and Cell Biology

The long non-coding RNA *LncHDAC2* drives the self-renewal of liver cancer stem cells via activation of Hedgehog signaling

J. Wu, P. Zhu, T. Lu, Y. Du, Y. Wang, L. He, B. Ye, B. Liu, L. Yang, J. Wang, Y. Gu, J. Lan, Y. Hao, L. He and Z. Fan 918

Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis

T. Gwag, Z. Meng, Y. Sui, R.N. Helsley, S.-H. Park, S. Wang, R.N. Greenberg and C. Zhou 930

Cholestasis and Autoimmune Diseases

Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis

T. Schmidt, D. Schwinge, T. Rolvien, A. Jeschke, C. Schmidt, M. Neven, S. Butscheidt, M. Kriz, L. Kunzmann, H. Mussawy, J. Hubert, T. Hawellek, W. R  ther, R. Oheim, F. Barvencik, A.W. Lohse, C. Schramm, T. Schinke and M. Amling 941

Genetic and Metabolic Diseases

Central role of the β -cell in driving regression of diabetes after liver transplantation in cirrhotic patients

V. Grancini, M. Trombetta, M.E. Lunati, M.L. Boselli, S. Gatti, M.F. Donato, E. Palmieri, V. Resi, G. Pugliese, R.C. Bonadonna and E. Orsi 954

Hepatic PPAR α is critical in the metabolic adaptation to sepsis

R. Paumelle, J.T. Haas, N. Hennuyer, E. Baug  , Y. Deleye, D. Mesotten, L. Langouche, J. Vanhoutte, C. Cudejko, K. Wouters, S.A. Hannou, V. Legry, S. Lancel, F. Lalloyer, A. Polizzi, S. Smati, P. Gourdy, E. Vallez, E. Bouchaert, B. Derudas, H. Dehondt, C. Gheeraert, S. Fleury, A. Tailleux, A. Montagner, W. Wahli, G. Van Den Berghe, H. Guillou, D. Dombrowicz and B. Staels 963

The non-transcriptional activity of IRF3 modulates hepatic immune cell populations in acute-on-chronic ethanol administration in mice

C. Sanz-Garcia, K.L. Poulsen, D. Bellos, H. Wang, M.R. McMullen, X. Li, S. Chattopadhyay, G. Sen and L.E. Nagy 974

REVIEWS

Autophagy in liver diseases: Time for translation?

M. Allaire, P.-E. Rautou, P. Codogno and S. Lotersztajn 985

Combined locoregional-immunotherapy for liver cancer

T.F. Greten, M. Mauda-Havakuk, B. Heinrich, F. Korangy and B.J. Wood 999

SPECIAL SECTIONS

Clinical Trial Watch

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

C. Yurdaydin, Z. Abbas, M. Buti, M. Cornberg, R. Esteban, O. Etzion, E.J. Gane, R.G. Gish, J.S. Glenn, S. Hamid, T. Heller, C. Koh, P. Lampertico, Y. Lurie, M. Manns, R. Parana, M. Rizzetto, S. Urban, H. Wedemeyer and on behalf of the Hepatitis Delta International Network (HDIN) 1008

Hepatology Snapshot

Digital pathology, what is the future?

V. Paradis and A. Quaglia 1016

LETTERS TO THE EDITOR

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

D. Wyles, O. Weiland, B. Yao, F. Weilert, J.-F. Dufour, S.C. Gordon, A. Stoehr, A. Brown, S. Mauss, Z. Zhang, T. Pilot-Matias, L. Rodrigues Jr, F.J. Mensa and F. Poordad 1019

Rabbit HEV in immunosuppressed patients with hepatitis E acquired in Switzerland

R. Sahli, M. Fraga, D. Semela, D. Moradpour and J. Gouttenoire 1023

Splenic artery aneurysms, portal hypertension and pregnancy

A. Morton 1025

Reply to: "Splenic artery aneurysms, portal hypertension and pregnancy"

F. Andrade, A. Shukla, C. Bureau, M. Senzolo, L. D'Alteroche, A. Heurgu  , F. Turon, J.-C. Garcia-Pagan, F. Oberti, D. Tripathi and P.-E. Rautou 1026

Prophylaxis of spontaneous bacterial peritonitis: Is there still room for quinolones?

A. Lombardi, V. Zuccaro, S. Fagioli and R. Bruno 1027

Reply to: "Prophylaxis of spontaneous bacterial peritonitis: is there still room for quinolones?"

P. Angeli and M. Bernardi 1028

Is *ex vivo* liver resection and autotransplantation a valid alternative treatment for end-stage hepatic alveolar echinococcosis in Europe?

G. Beldi, D. Vuitton, A. Lachenmayer, B. Heyd, J.-F. Dufour, C. Richou, D. Candinas and S. Bresson-Hadni 1030

Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia

S.P. Singh, S. Panigrahi, D. Mishra and C.R. Khatua 1031

Reply to: "Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia"

H. Devarbhavi, S.K. Asrani and P.S. Kamath 1033

The UK DCD Risk Score: Still no consensus on futility in DCD liver transplantation

A.J. Hessheimer, E. Coll, P. Ru  z, M. Gastaca, J.I. Rivas, M. G  mez, B. S  nchez, J. Santoyo, P. Ram  rez, P. Parrilla, L.M. Mar  n, M.  . G  mez-Bravo, J.C. Garc  a-Valdecasas, J. L  pez-Moncl  s, A. Bosc  , R. L  pez-And  jar, J. Fundora-Su  rez, J. Villar,   . Garc  a-Sesma, C. Jim  nez, G. Rodr  guez-Laiz, L. Llad  , J.C. Rodr  guez, M. Barrera, R. Charco, J.  . L  pez-Baena, J. Brice  o, F. Pardo, G. Blanco, D. Pacheco, B. Dom  nguez-Gil, V. S  nchez Turri  n and C. Fondevila 1034

Reply to: "The UK DCD Risk Score: Still no consensus on futility in DCD liver transplantation"

A. Schlegel and P. Muiesan 1036

Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.

Cover image: Association between physical activity and risk of hepatobiliary cancers: A multinational cohort study, by S.E. Baumeister et al. on pp. 885–892 in this issue.

Cover design: 3D representation of the correlation between exercise and liver health. By Caitlin Monney.